Physician profile
Vikram D Gopal
NPI 1720041247
$14,143.33
in general payments reported to CMS, 2019-2025
33 companies · $6,107 in 2025
The $6,107 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $412 · 2021: $809 · 2022: $722 · 2023: $957 · 2024: $4,277 · 2025: $6,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,401 · Food and Beverage: $4,918 · Education: $20.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,401.10 |
| Food and Beverage | $4,917.93 |
| Education | $20.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,227.30 | 2019-2025 | Overstitch Endoscopic Suturing System, Overstitch Nxt Endoscopic Suturing System, General - Biliary Devices |
| Medtronic, INC. | $3,115.85 | 2021-2025 | Gi Genius |
| Enterra Medical, INC. | $2,737.13 | 2023-2025 | |
| Abbvie INC. | $1,267.95 | 2019-2025 | |
| Madrigal Pharmaceuticals | $427.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $347.09 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $219.30 | 2019-2024 | Ocaliva |
| Janssen Biotech, INC. | $188.06 | 2023-2025 | Stelara, Tremfya |
| Apollo Endosurgery US INC | $181.44 | 2022-2023 | Orbera Intragastric Balloon System, Overstitch Endoscopic Suturing System |
| Gilead Sciences, INC. | $179.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.34 | 2021-2024 | Xifaxan |
| Celgene Corporation | $142.56 | 2021-2023 | Zeposia |
| Medtronic USA, INC. | $135.74 | 2019 | |
| Olympus America INC. | $95.03 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.50 | 2019-2023 | Gattex |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $88.79 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $73.26 | 2023-2024 | Dupixent |
| Pfizer INC. | $68.77 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $62.80 | 2021-2024 | Dificid |
| Ardelyx, INC. | $52.44 | 2023-2025 | Ibsrela |
| Vivus LLC | $47.05 | 2021-2024 | Qsymia |
| Ironwood Pharmaceuticals, INC | $35.55 | 2022 | |
| Lilly USA, LLC | $32.30 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $29.55 | 2021 | |
| Daiichi Sankyo INC. | $22.72 | 2024 | Injectafer |
| Celltrion USA INC. | $20.88 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $16.79 | 2025 | Iqirvo |
| Ambu INC. | $15.76 | 2021 | |
| Amgen INC. | $14.38 | 2025 | Uplizna |
| Shionogi INC | $13.30 | 2020 | |
| Redhill Biopharma INC. | $12.72 | 2021 | |
| Allergan, INC. | $11.88 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.